Trials / Conditions / Carcinoma in Situ of Bladder
Carcinoma in Situ of Bladder
6 registered clinical trials studyying Carcinoma in Situ of Bladder — 2 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Not Yet Recruiting | Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients NCT07231809 | AC.TA. S.r.l. | N/A |
| Not Yet Recruiting | Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC NCT07189793 | First Affiliated Hospital of Wenzhou Medical University | Phase 2 |
| Completed | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIB NCT05375903 | UroGen Pharma Ltd. | Phase 1 |
| Terminated | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Tre NCT03335059 | Medical Enterprises Ltd. | Phase 3 |
| Terminated | Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the NCT02901548 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Retrospective Chart Review of Valstar NCT01304173 | Endo Pharmaceuticals | — |